VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-14 · 10 min read

Telmisartan for Cats: Proteinuria, Blood Pressure, and CKD Monitoring

Telmisartan (Semintra) for cats — FDA-approved for hypertension, used off-label for CKD proteinuria. Dosing, monitoring, and the benazepril comparison.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Telmisartan (brand name Semintra) is an angiotensin II receptor blocker (ARB) that has become central to managing two linked problems in cats with chronic kidney disease (CKD): systemic hypertension and proteinuria. Semintra oral solution is FDA-approved for the control of systemic hypertension in cats. Its use for CKD-associated proteinuria is off-label in the United States but is licensed for that indication in Europe, Canada, and the United Kingdom — and is supported by a randomized controlled trial showing non-inferiority to benazepril.

This article covers what telmisartan does, when veterinarians reach for it, how it is dosed and monitored, and what the evidence says about using it versus an ACE inhibitor like benazepril.

Quick answer

Semintra is a once-daily (after a two-week loading phase) oral liquid labeled for feline hypertension. It blocks the angiotensin II type 1 receptor, lowering blood pressure and reducing pressure inside the kidney's filtering units (glomeruli). For cats with CKD who are also leaking protein into their urine — a negative prognostic indicator — telmisartan at 1 mg/kg once daily has been shown in a multicenter trial of 224 cats to be non-inferior to benazepril at reducing the urine protein-to-creatinine ratio (UPC).

Key monitoring parameters: systolic blood pressure, serum creatinine and SDMA, electrolytes (especially potassium), UPC ratio, and hematocrit.

The two problems telmisartan addresses in CKD cats

Systemic hypertension

CKD is the most common cause of systemic hypertension in cats. The kidneys regulate blood pressure through the renin-angiotensin-aldosterone system (RAAS). As kidney function declines, the body activates RAAS to maintain glomerular filtration rate, which raises systemic blood pressure. Left untreated, hypertension causes target organ damage: retinal detachment (sudden blindness), progressive CKD, and neurological signs.

The International Society of Feline Medicine (ISFM) and the International Renal Interest Society (IRIS) recommend treating hypertension when systolic blood pressure (SBP) is persistently above 160 mmHg, and the FelineVMA Hypertension Toolkit identifies amlodipine and telmisartan as first-line options.

Proteinuria

Protein in the urine — specifically a UPC ratio above 0.4 in a cat with CKD — is an independent risk factor for faster disease progression and shorter survival. Proteinuria reflects increased pressure and damage within the glomerulus. Blocking angiotensin II reduces intraglomerular pressure and decreases protein leakage, independent of the effect on systemic blood pressure.

Not every CKD cat is proteinuric. But when a cat has both hypertension and an elevated UPC, a single agent that addresses both is clinically useful.

How telmisartan works

Angiotensin II is the effector hormone of the RAAS. It constricts blood vessels, stimulates aldosterone release, promotes sodium retention, and preferentially constricts the efferent arteriole of the glomerulus — raising intraglomerular pressure. In CKD, chronic RAAS activation drives both hypertension and glomerular injury.

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor. The result is:

  • Vasodilation (lower systemic blood pressure)
  • Reduced aldosterone secretion
  • Decreased efferent arteriolar resistance (lower intraglomerular pressure, less protein leak)

This mechanism is similar to what ACE inhibitors (benazepril, enalapril) achieve, but at a different point in the pathway. ACE inhibitors block the enzyme that converts angiotensin I to angiotensin II. ARBs block the receptor directly. The theoretical advantage of the ARB approach is that it blocks angiotensin II activity regardless of how it was produced (ACE-independent pathways exist), and it does not interfere with bradykinin metabolism — which means a lower incidence of cough and potentially fewer GI side effects.

FDA-approved vs. off-label use

Indication Regulatory status (US) Dose
Control of systemic hypertension in cats FDA-approved (Semintra, NADA 141-501, approved May 2018) 1.5 mg/kg PO q12h for 14 days, then 2 mg/kg PO q24h
Reduction of proteinuria in CKD cats Off-label (licensed in EU, UK, Canada) 1 mg/kg PO q24h

The hypertension dose starts higher and then steps down. The proteinuria dose is lower and given once daily from the start. In practice, some veterinarians start at a lower dose for hypertension than the label recommends, particularly in cats who are not severely hypertensive, and titrate upward based on blood pressure response.

Evidence: telmisartan vs. benazepril

The key trial for the proteinuria comparison is Sent et al. (2015), published in the Journal of Veterinary Internal Medicine. This was a prospective, multicenter, randomized, blinded, parallel-group study of 224 cats with CKD (primarily IRIS stage 2). Key findings:

  • Cats received either telmisartan (1 mg/kg, n=112) or benazepril (0.5–1.0 mg/kg, n=112) once daily for 180 days.
  • Telmisartan was non-inferior to benazepril for the primary endpoint (change in UPC).
  • Telmisartan significantly decreased UPC relative to baseline at all assessment points. Benazepril did not show a statistically significant decrease at any assessment point.
  • Both drugs were well tolerated. Dropout rates were similar (15% telmisartan vs. 19.8% benazepril).

For hypertension specifically, the effectiveness data supporting the FDA approval showed that Semintra reduced systolic blood pressure by an average of approximately 19–23 mmHg by day 14, with more than 50% of treated cats achieving SBP below 150 mmHg by day 28. Long-term response rates exceeded 60% over six months.

Important caveat: telmisartan has not been evaluated as a single agent for cats with systolic blood pressure above 200 mmHg. In those patients, amlodipine remains the standard first-line drug.

Dosing in practice

Hypertension (labeled)

  1. Start at 1.5 mg/kg PO every 12 hours for 14 days.
  2. After the loading phase, reduce to 2 mg/kg PO every 24 hours.
  3. If SBP falls below 120 mmHg, decrease by 0.5 mg/kg increments. The minimum dose is 0.5 mg/kg once daily.

Proteinuria (off-label)

  1. Start at 1 mg/kg PO every 24 hours.
  2. Monitor UPC at 2–4 weeks.
  3. If UPC is not improving, titrate upward in 0.5 mg/kg increments, up to 2 mg/kg once daily.
  4. Monitor blood pressure concurrently — the proteinuria dose can also lower blood pressure, and iatrogenic hypotension is a risk.

Semintra comes as a 10 mg/mL oral liquid with a calibrated dosing syringe. It can be given directly into the mouth or placed on top of a small amount of food. The label specifies not to mix it into food. If the cat vomits within 30 minutes of dosing, the dose can be repeated.

Monitoring

Monitoring is not optional with an ARB. The same mechanism that lowers blood pressure and intraglomerular pressure can also reduce glomerular filtration rate — which means azotemia can worsen, especially early in treatment or if the cat is dehydrated.

What to check and when

Timing What to monitor
Baseline (before starting) SBP, creatinine, SDMA, BUN, electrolytes (potassium, sodium), UPC, CBC, urine specific gravity, hematocrit
7–14 days after start or dose change SBP, creatinine, electrolytes. UPC if treating proteinuria.
Every 3–6 months ongoing Full panel (CBC, chemistry, urinalysis, UPC, SBP)

Red flags that warrant a recheck before the scheduled visit

  • Worsening azotemia (rise in creatinine >0.5 mg/dL from baseline or >25% increase in SDMA)
  • Hyperkalemia (potassium >6.0 mEq/L) — more likely if combined with an ACE inhibitor or spironolactone
  • Hypotension (SBP <120 mmHg) — lethargy, weakness, fainting
  • Progressive weight loss, anemia (declining hematocrit), or inappetence

Side effects

From the FDA approval field study and post-marketing experience:

  • Gastrointestinal signs: vomiting, regurgitation, diarrhea, soft stools. These are the most commonly reported and are often mild.
  • Weight loss and dehydration — may reflect the underlying CKD rather than drug effect, but should prompt recheck.
  • Mild, non-regenerative anemia — monitor hematocrit.
  • Lethargy — may indicate hypotension.

Serious adverse effects are uncommon but include acute kidney injury (particularly if given to a dehydrated cat or combined with an NSAID) and severe hypotension.

Drug interactions that matter

Combination Concern
ACE inhibitor (benazepril, enalapril) Dual RAAS blockade. Additive reduction in GFR. Risk of acute kidney injury and hyperkalemia. Some specialists use this combination cautiously in severely proteinuric cats, but it requires close monitoring.
NSAID (meloxicam, robenacoxib, etc.) Cumulative decrease in renal perfusion. Both classes reduce blood flow to the kidney through different mechanisms. Avoid concurrent use if possible; if unavoidable, monitor renal values within 5–7 days.
Amlodipine Often combined safely. May have additive antihypertensive effect — monitor for hypotension when starting or increasing either drug.
Spironolactone Theoretical risk of hyperkalemia. Use with caution and monitor electrolytes.
Digoxin In humans, telmisartan increases plasma digoxin concentrations. Use with caution in cats receiving digoxin (rare but possible in cardiology cases).

When telmisartan is not the right fit

  • Cats with SBP consistently above 200 mmHg — amlodipine is preferred as a single agent until blood pressure is below this threshold.
  • Cats that are dehydrated, hypotensive, or in acute kidney injury — stabilize first.
  • Cats with severe liver disease — telmisartan is hepatically metabolized.
  • Pregnant or lactating cats — substances acting on the RAAS can cause fetal and neonatal morbidity. Pregnant humans should avoid handling the drug.
  • Cats already on an ACE inhibitor where the veterinarian is not prepared to monitor for dual RAAS blockade effects.

Practical decisions: what to ask your veterinarian

If your cat has CKD and either hypertension or proteinuria, these are the questions worth raising:

  • What is my cat's current UPC ratio and systolic blood pressure? These two numbers drive the decision. A UPC above 0.4 with CKD warrants intervention. SBP persistently above 160 mmHg requires treatment.
  • Would telmisartan or an ACE inhibitor be more appropriate? For a cat with hypertension as the primary concern, telmisartan's liquid formulation and FDA-approved indication make it a straightforward choice. For proteinuria without hypertension, either class may be appropriate; the trial data slightly favor telmisartan on the UPC endpoint.
  • How soon after starting should we recheck? Blood pressure and renal values should be checked within 7–14 days of starting or adjusting the dose.
  • Is my cat on any other medications that could interact? NSAIDs, ACE inhibitors, and potassium supplements are the main ones to flag.

Sources

Topics
Feline CKD
Related Articles